Update in Cardiology
Authors: Robert L. Frye
Journal: Annals of Internal Medicine (2007)

Updates7 August 2007Update in CardiologyRobert L. Frye, MD*Robert L. Frye, MD*From the Mayo Clinic, Rochester, Minnesota.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-147-3-200708070-00007 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail This update in clinical cardiology focuses on topics of interest and importance to practicing internists. The Table summarizes conclusions to consider for your practice.Table. Changes to Clinical Practice Emerging from Articles Important to Cardiologists in 2006Ischemic Heart DiseaseOccluded Artery Trial Investigators.Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med. 2006;355:2395-407. [PMID: 17105759]Question: Does percutaneous coronary intervention (PCI) reduce the incidence of adverse cardiovascular events in patients with myocardial infarction who present after 72 hours?Study Design: Randomized, controlled trial.Patients: 2166 patients who presented 3 ...References1. Angina With Extremely Serious Operative Mortality Evaluation (AWESOME). Percutaneous coronary intervention versus coronary artery bypass graft surgery for patients with medically refractory myocardial ischemia and risk factors for adverse outcomes with bypass: a multicenter, randomized trial. Investigators of the Department of Veterans Affairs Cooperative Study #385, the Angina With Extremely Serious Operative Mortality Evaluation (AWESOME). J Am Coll Cardiol. 2001;38:143-9. [PMID: 11451264] MedlineGoogle Scholar2. Department of Veterans Affairs Angina With Extremely Serious Operative Mortality (AWESOME) Investigators. Health-related quality of life after percutaneous coronary intervention versus coronary bypass surgery in high-risk patients with medically refractory ischemia. J Am Coll Cardiol. 2003;41:1732-8. [PMID: 12767656] CrossrefMedlineGoogle Scholar3. Fitzgerald GA. Coxibs and cardiovascular disease. N Engl J Med. 2004;351:1709-11. [PMID: 15470192] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: Robert L. Frye, MD*Affiliations: From the Mayo Clinic, Rochester, Minnesota.*Adapted for publication in Annals of Internal Medicine by Jennifer Fisher Wilson and Michael Berkwits, MD, MSCE.Corresponding Author: Robert L. Frye, MD, Mayo Clinic, Siebens Building, Room 640, 200 First Street SW, Rochester, MN 55905; e-mail, rfrye@mayo.edu.Disclosures: Consultancies: Cleveland Clinic, Sanofi-Synthelabo Research. Honoraria: Cleveland Clinic, Sanofi-Synthelabo Research; all honoraria were paid to the Mayo Clinic and not the author. Grants received: Abbott Laboratories, Bayer Diagnostics, Becton Dickinson, Centocor, Bristol-Myers Squibb Medical Imaging (formerly DuPont), Eli Lilly and Company, Fujisawa Healthcare, GlaxoSmithKline, Merck & Co., Pfizer; all were received in support of BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes), a National Heart, Lung, and Blood Institute and National Institute of Diabetes and Digestive and Kidney Diseases Clinical Trial. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 7 August 2007Volume 147, Issue 3Page: 180-186KeywordsACE inhibitorsAtrial fibrillationDrug therapyDrugsHazard ratioMyocardial infarctionNSAIDsPercutaneous coronary interventionStent implantationVeins ePublished: 7 August 2007 Issue Published: 7 August 2007 Copyright & PermissionsCopyright © 2007 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...